Key Points
- Naimish Patel, a CRISPR Therapeutics insider, purchased 1,508 shares on April 3 at an average price of $32.96, totaling $49,703.68, representing an apparent first-time (∞) increase in his ownership.
- CRISPR shares trade around $54.26 (52‑week range $30.04–$78.48) with a market cap of $5.17B, but the company remains unprofitable and carries a consensus analyst rating of "Hold" with an average price target of $68.15.
CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) insider Naimish Patel bought 1,508 shares of CRISPR Therapeutics stock in a transaction that occurred on Thursday, April 3rd. The stock was bought at an average price of $32.96 per share, for a total transaction of $49,703.68. Following the completion of the acquisition, the insider directly owned 1,508 shares of the company's stock, valued at $49,703.68. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.
CRISPR Therapeutics Stock Performance
Shares of NASDAQ CRSP opened at $54.26 on Wednesday. The company's 50 day moving average price is $54.94 and its 200-day moving average price is $58.35. CRISPR Therapeutics AG has a 52-week low of $30.04 and a 52-week high of $78.48. The company has a market capitalization of $5.17 billion, a P/E ratio of -9.71 and a beta of 1.70.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.17) earnings per share for the quarter, topping the consensus estimate of ($1.32) by $0.15. The company had revenue of $0.89 million during the quarter, compared to analysts' expectations of $8.74 million. CRISPR Therapeutics had a negative net margin of 1,273.70% and a negative return on equity of 21.23%. Analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.
Analyst Ratings Changes
Several equities research analysts recently commented on the company. Citizens Jmp restated a "market outperform" rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, December 23rd. Bank of America dropped their price target on CRISPR Therapeutics from $90.00 to $89.00 and set a "buy" rating on the stock in a research note on Thursday, January 22nd. Royal Bank Of Canada increased their price target on CRISPR Therapeutics from $42.00 to $50.00 and gave the stock a "sector perform" rating in a report on Tuesday, November 11th. Wedbush lowered their price objective on shares of CRISPR Therapeutics from $13.00 to $9.00 and set an "outperform" rating for the company in a research note on Wednesday, November 5th. Finally, Needham & Company LLC reissued a "buy" rating and set a $80.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, December 23rd. Twelve investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $68.15.
Check Out Our Latest Stock Report on CRSP
Hedge Funds Weigh In On CRISPR Therapeutics
Large investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in CRISPR Therapeutics by 5.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,516 shares of the company's stock worth $228,000 after buying an additional 180 shares during the last quarter. IFP Advisors Inc grew its holdings in shares of CRISPR Therapeutics by 24.6% during the second quarter. IFP Advisors Inc now owns 916 shares of the company's stock valued at $45,000 after buying an additional 181 shares during the last quarter. Cerity Partners LLC increased its position in shares of CRISPR Therapeutics by 3.0% during the second quarter. Cerity Partners LLC now owns 6,541 shares of the company's stock worth $318,000 after acquiring an additional 190 shares in the last quarter. Peapack Gladstone Financial Corp raised its holdings in shares of CRISPR Therapeutics by 3.0% in the 2nd quarter. Peapack Gladstone Financial Corp now owns 6,973 shares of the company's stock worth $339,000 after acquiring an additional 200 shares during the last quarter. Finally, Optiver Holding B.V. lifted its position in CRISPR Therapeutics by 71.4% in the 3rd quarter. Optiver Holding B.V. now owns 504 shares of the company's stock valued at $33,000 after acquiring an additional 210 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors.
About CRISPR Therapeutics
(
Get Free Report)
CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.
Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
